CN108883167A - 用于预防和治疗外阴阴道念珠菌病的方法和药剂盒 - Google Patents
用于预防和治疗外阴阴道念珠菌病的方法和药剂盒 Download PDFInfo
- Publication number
- CN108883167A CN108883167A CN201780020274.9A CN201780020274A CN108883167A CN 108883167 A CN108883167 A CN 108883167A CN 201780020274 A CN201780020274 A CN 201780020274A CN 108883167 A CN108883167 A CN 108883167A
- Authority
- CN
- China
- Prior art keywords
- als3
- thr
- polypeptide
- subject
- micrograms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305714P | 2016-03-09 | 2016-03-09 | |
| US62/305,714 | 2016-03-09 | ||
| PCT/US2017/021094 WO2017155949A1 (en) | 2016-03-09 | 2017-03-07 | Methods and kits for use in preventing and treating vulvovaginal candidiasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108883167A true CN108883167A (zh) | 2018-11-23 |
Family
ID=59790870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780020274.9A Pending CN108883167A (zh) | 2016-03-09 | 2017-03-07 | 用于预防和治疗外阴阴道念珠菌病的方法和药剂盒 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10857216B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3426287A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019507759A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108883167A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017155949A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070077256A1 (en) | 1999-11-19 | 2007-04-05 | Los Angeles Biomedical Research Institute | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
| EP2734229B1 (en) | 2011-07-22 | 2019-01-02 | Novadigm Therapeutics, Inc. | Methods and copositions for vaccinating against staphylococcus aureus |
| BR112015022963A8 (pt) | 2013-03-15 | 2018-01-16 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | composições e métodos para tratar patógenos fúngicos e bacterianos. |
| WO2017155949A1 (en) | 2016-03-09 | 2017-09-14 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Methods and kits for use in preventing and treating vulvovaginal candidiasis |
| JP7439371B2 (ja) * | 2018-04-10 | 2024-02-28 | ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー- ユーシーエルエー メディカル センター | Candida auris感染症の治療方法 |
| EP3552620A1 (en) * | 2018-04-11 | 2019-10-16 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Methods of treatment for candida auris infections |
| WO2022140646A1 (en) * | 2020-12-26 | 2022-06-30 | Mycovia Pharmaceuticals, Inc | Dosing regimen for oteseconazole |
| JP2022191716A (ja) | 2021-06-16 | 2022-12-28 | ローム・アンド・ハース・エレクトロニック・マテリアルズ・コリア・リミテッド | Uv硬化性シリコーン組成物及びその硬化物 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4346074A (en) | 1978-08-24 | 1982-08-24 | National Research Development Corp. | Pasteurellosis vaccines |
| US5622939A (en) | 1992-08-21 | 1997-04-22 | Alpha-Beta Technology, Inc. | Glucan preparation |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| WO1995031998A1 (en) | 1994-05-23 | 1995-11-30 | The Research & Development Institute, Inc. | Candida albicans adhesin as a vaccine |
| US5668263A (en) | 1994-12-16 | 1997-09-16 | Smithkline Beecham Corporation | Conserved yeast nucleic acid sequences |
| US6500438B2 (en) | 1995-06-07 | 2002-12-31 | Pfizer Incorporated | In ovo vaccination against coccidiosis |
| US6288214B1 (en) | 1996-05-16 | 2001-09-11 | Texas A&M University Systems | Collagen binding protein compositions and methods of use |
| WO1998009990A1 (en) * | 1996-09-04 | 1998-03-12 | Takara Shuzo Co., Ltd. | Fungal antigens and process for producing the same |
| US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
| US6248329B1 (en) | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| US6703025B1 (en) | 1998-08-31 | 2004-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
| US20070077256A1 (en) | 1999-11-19 | 2007-04-05 | Los Angeles Biomedical Research Institute | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
| US8541008B2 (en) | 1999-11-19 | 2013-09-24 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against candidiasis |
| US7067138B1 (en) | 1999-11-19 | 2006-06-27 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis |
| US20060083750A1 (en) | 1999-11-19 | 2006-04-20 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis |
| JP3717104B2 (ja) | 2000-05-30 | 2005-11-16 | シャープ株式会社 | 回路内蔵受光素子 |
| FR2814741B1 (fr) | 2000-09-29 | 2004-02-27 | Atofina | Procede de stabilisation de monomeres acryliques |
| US6579820B2 (en) | 2001-03-21 | 2003-06-17 | The Boc Group, Inc. | Reactor modifications for NOx reduction from a fluid catalytic cracking regeneration vessel |
| ES2645563T3 (es) | 2001-11-30 | 2017-12-05 | Amgen Fremont Inc. | Animales transgénicos que portan genes de cadena ligera de Ig humana |
| DE10216281B4 (de) | 2002-04-12 | 2007-04-12 | Noé, Reinhold, Prof. Dr.-Ing. | Anordnung und Verfahren für eine Dispersionsdetektion |
| CA2486618C (en) | 2002-05-21 | 2013-04-09 | Schering-Plough Ltd. | Methods for the in vitro culture of sporozoea sp. and uses thereof |
| US7241613B1 (en) | 2002-06-05 | 2007-07-10 | Oscient Pharmaceuticals Corporation | Identification of Candida cell surface proteins and their uses |
| AU2003290867A1 (en) | 2002-11-12 | 2004-06-03 | The Brigham And Women's Hospital, Inc. | Methods and products for treating staphylococcal infections |
| US6935255B2 (en) | 2003-08-08 | 2005-08-30 | Deere & Company | Auxiliary seed hopper having a removable screen |
| BRPI0416205A (pt) | 2003-11-21 | 2006-12-26 | Pfizer Prod Inc | uso de antibióticos como adjuvantes de vacina |
| US20050287146A1 (en) | 2003-12-19 | 2005-12-29 | Joseph Patti | Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions |
| GB0420466D0 (en) | 2004-09-14 | 2004-10-20 | Cassone Antonio | Anti-glucan antibodies |
| WO2006036817A2 (en) | 2004-09-24 | 2006-04-06 | Microbia, Inc. | Fungal variants and uses thereof |
| CA2489194A1 (en) | 2004-12-03 | 2006-06-03 | Guilhem Janbon | Polypeptides involved in candida biofilm formation and uses thereof |
| US7971912B2 (en) | 2005-04-07 | 2011-07-05 | Sanoh Kogyo Kabushiki Kaisha | Quick connector |
| US7320467B2 (en) | 2005-06-03 | 2008-01-22 | Mattel, Inc. | Narrating games |
| WO2007126813A2 (en) | 2006-03-29 | 2007-11-08 | Inhibitex, Inc. | Cross-reactive monoclonal antibodies recognizing als family proteins |
| WO2007123850A2 (en) | 2006-04-17 | 2007-11-01 | Schering-Plough Ltd. | Recombinant attenuated clostridium organisms and vaccine |
| US8470790B2 (en) | 2006-05-04 | 2013-06-25 | Wayne State University | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
| NZ598927A (en) | 2007-01-12 | 2013-09-27 | Biocryst Pharm Inc | Antiviral nucleoside analogs |
| WO2008147847A1 (en) | 2007-05-22 | 2008-12-04 | Baylor College Of Medicine | Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations |
| EP2296698A1 (en) | 2008-05-29 | 2011-03-23 | Intervet International BV | Coccidiosis vaccines |
| US20100150942A1 (en) | 2008-12-03 | 2010-06-17 | Cantor Thomas L | Affinity purified human polyclonal antibodies and methods of making and using them |
| AU2010264538B2 (en) | 2009-06-22 | 2013-10-03 | Wyeth Llc | Immunogenic compositions of Staphylococcus aureus antigens |
| ES2606555T3 (es) | 2009-07-03 | 2017-03-24 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | HYR1 como objetivo para la inmunización activa y pasiva contra Candida |
| US9462734B2 (en) | 2010-04-27 | 2016-10-04 | Alion Energy, Inc. | Rail systems and methods for installation and operation of photovoltaic arrays |
| EP2403118A3 (en) | 2010-07-01 | 2014-10-29 | Kabushiki Kaisha Yaskawa Denki | Actuator |
| KR101075495B1 (ko) | 2010-07-06 | 2011-10-21 | 주식회사 하이닉스반도체 | 반도체 모듈에 포함된 다수의 반도체 장치를 선택하는 회로 및 그 동작방법 |
| US20120023753A1 (en) | 2010-08-02 | 2012-02-02 | Hao Wen | knife having a locking mechanism |
| WO2012163533A1 (en) | 2011-06-01 | 2012-12-06 | Eth Zurich | T cell epitope of candida albicans |
| EP2734229B1 (en) * | 2011-07-22 | 2019-01-02 | Novadigm Therapeutics, Inc. | Methods and copositions for vaccinating against staphylococcus aureus |
| AU2012308281A1 (en) | 2011-09-14 | 2014-04-24 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Hyr1-derived compositions and methods of treatment using same |
| WO2014144024A1 (en) | 2013-03-15 | 2014-09-18 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Hyr1 compositions and methods for treating fungal and bacterial pathogens |
| BR112015022963A8 (pt) | 2013-03-15 | 2018-01-16 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | composições e métodos para tratar patógenos fúngicos e bacterianos. |
| US20160030533A1 (en) | 2013-03-15 | 2016-02-04 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Compositions and methods of treating fungal and bacterial pathogens |
| GB201503812D0 (en) | 2015-03-06 | 2015-04-22 | Univ Aberdeen | Antibody molecules and uses thereof |
| WO2017155949A1 (en) | 2016-03-09 | 2017-09-14 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Methods and kits for use in preventing and treating vulvovaginal candidiasis |
-
2017
- 2017-03-07 WO PCT/US2017/021094 patent/WO2017155949A1/en not_active Ceased
- 2017-03-07 EP EP17763871.5A patent/EP3426287A4/en not_active Withdrawn
- 2017-03-07 JP JP2018544888A patent/JP2019507759A/ja active Pending
- 2017-03-07 CN CN201780020274.9A patent/CN108883167A/zh active Pending
- 2017-03-07 US US16/081,062 patent/US10857216B2/en active Active
Non-Patent Citations (2)
| Title |
|---|
| ASHRAF S. IBRAHIM等: "NDV-3 Protects Mice From Vulvovaginal Candidiasis Through T-and B-Cell Immune Response", 《VACCINE》 * |
| CLINT S.SCHMIDT等: "NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus,is safe and immunogenic in healthy adults", 《VACCINE》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US10857216B2 (en) | 2020-12-08 |
| EP3426287A4 (en) | 2020-03-11 |
| JP2019507759A (ja) | 2019-03-22 |
| EP3426287A1 (en) | 2019-01-16 |
| WO2017155949A1 (en) | 2017-09-14 |
| US20190076512A1 (en) | 2019-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10857216B2 (en) | Methods and kits for use in preventing and treating vulvovaginal candidiasis | |
| ES2748381T3 (es) | Polipéptido(s) llevado(s) por CYAA y uso para inducir respuestas inmunitarias terapéuticas y profilácticas | |
| AU2011234656B2 (en) | Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant | |
| JP2020533340A (ja) | サポニンを含むリポソーム製剤および使用方法 | |
| WO2021216467A1 (en) | A nano-enabled vaccination approach for coronavirus disease (covid-19) and other viral diseases | |
| TW201630621A (zh) | Kv1.3通道阻斷肽之局部施用以治療皮膚發炎 | |
| US20220111028A1 (en) | Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist | |
| US20250268998A1 (en) | Methods of treatment for candida auris infections | |
| JP2019110918A (ja) | 真菌病原体および細菌病原体を処置するための組成物および方法 | |
| Zhong et al. | Nasal delivery of an immunotherapeutic vaccine in thermosensitive hydrogel against allergic asthma | |
| US9707284B2 (en) | Formulations of peptides and chloroquines for the treatment of pathogenic immune responses in immune mediated diseases | |
| US20190117749A1 (en) | PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRa-EXPRESSING TUMORS | |
| US12180284B2 (en) | Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector | |
| WO2008070902A1 (en) | Tgf-beta compositions for treating infertility | |
| AU2018225163A1 (en) | Peptides and methods of treating dystrophy-related disorders using the same | |
| EP3552620A1 (en) | Methods of treatment for candida auris infections | |
| EP4445910A1 (en) | Vaccine composition for inducing anti-il-23 antibody | |
| US20230011870A1 (en) | Nanovaccine for heart failure | |
| Jerajani | Design and Development of Low-Cost Multi-Dose Human Papillomavirus Vaccine Formulations Containing Antimicrobial Preservatives | |
| US11338025B2 (en) | Vaccine therapy for treatment of endometrial and ovarian cancer | |
| HK40015673A (en) | Methods of treatment for candida auris infections | |
| AU2013221980A1 (en) | Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181123 |
|
| WD01 | Invention patent application deemed withdrawn after publication |